Aytu BioPharma explores strategic alternatives and financing to address liquidity; SEC inquiry ongoing

AYTU BIOPHARMA, INC

Preliminary discussions underway for potential strategic transactions and financing options.
Company cites ongoing liquidity needs; no assurance that any deal will materialize.
Equity financings would provide liquidity but could be dilutive to existing stockholders.
SEC inquiry active regarding proposed restatements; timing of restatement and Q2 10-Q filing uncertain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.